Vanda Pharmaceuticals Inc

VNDA

Healthcare|Biotechnology|USA

$6.24

-0.14 (-2.19%)

DCF (FCF)

$3.02

Tangible Book

$2.76

Earnings Power

$1.56

Clinical Trials (85)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT05648591 Safety and Tolerability of Open-Labeled Iloperidone in Adolescents	Schizophrenia, Bipolar I Disorder	P4	Recruiting	100	Open-label	Iloperidone
NCT06961968 Randomized Withdrawal Study in Patients With Schizophrenia	Schizophrenia	P3	Recruiting	400	RCT, Double-blind	iloperidone, placebo
NCT06138613 Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness	Motion Sickness	P3	Active	705	RCT, Open-label	Tradipitant
NCT06701396 Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant	Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm	P3	Recruiting	60	RCT, Double-blind	Tasimelteon, Placebo
NCT07446439 A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use	Nausea and Vomiting, Obesity	P3	Recruiting	280	RCT, Double-blind	Tradipitant, Placebo
NCT04652882 Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)	Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm	P3	Recruiting	70	RCT, Double-blind	Tasimelteon, Placebo
NCT06953869 Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia	Insomnia Disorder	P3	Recruiting	420	RCT, Double-blind	Tasimelteon Oral Suspension, Placebo
NCT06830044 Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder	Major Depressive Disorder (MDD)	P3	Recruiting	500	RCT, Double-blind	Milsaperidone, Placebo
NCT07221578 Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder	Social Anxiety Disorder (SAD)	P3	Recruiting	500	RCT, Double-blind	VQW-765, Placebo
NCT06836557 Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis	Idiopathic Gastroparesis, Diabetic Gastroparesis	P3	Recruiting	100	Open-label	Tradipitant
NCT07362017 Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis	Moderate-to-severe Chronic Plaque Psoriasis	P3	Recruiting	300	Open-label	Ponesimod
NCT07065773 Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis	Onychomycosis of Toenail	P2	Active	50	Open-label	Trichostatin A
NCT07179055 An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye	Dry Eye	P2	Recruiting	160	RCT, Double-blind	VSJ-110, Placebo
NCT07090161 Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension	Hypertension, Uncontrolled Hypertension	P2	Recruiting	240	RCT, Double-blind	iloperidone, Placebo
NCT07223632 Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient	Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (NMD)	P1P2	Active	1	Open-label	VCA-894A
NCT03838926 Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies	Relapsed or Refractory Hematologic Malignancies	P1	Recruiting	42	Open-label	Trichostatin A
NCT01195558 Patient Registry of Blind Subjects With Sleep-related Problems	Sleep-wake Disorder in Blind Individuals		Recruiting	10,000	—	—
NCT03154697 Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances	Sleep Disturbances in Smith-Magenis Syndrome		Recruiting	1,000	—	—
NCT02130999 Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)	Non-24-Hour-Sleep-Wake Disorder	P4	Completed	14	RCT, Open-label	tasimelteon 20 mg capsule, tasimelteon 2 mg I.V.
NCT02413918 Iloperidone in Mixed States of Bipolar Disorder	Bipolar Disorder	P4	Completed	41	Open-label	iloperidone
NCT04326426 ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection	Coronavirus Infection	P3	By Invite	300	RCT, Double-blind	Tradipitant, Placebo
NCT01430754 Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder	Non-24-Hour Sleep-Wake Disorder	P3	Completed	20	RCT, Double-blind	tasimelteon, Placebo
NCT01429116 Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception	Non-24-Hour Sleep-Wake Disorder	P3	Completed	200	Open-label	tasimelteon
NCT04327661 Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness	Motion Sickness	P3	Completed	366	RCT, Double-blind	Tradipitant, Placebo
NCT03568331 Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)	Atopic Dermatitis	P3	Completed	375	RCT, Double-blind	Tradipitant, Placebo
NCT05366855 Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP	Generalized Pustular Psoriasis	P3	Terminated	42	RCT, Double-blind	Double-blind 200 mg imsidolimab, Open-label 200 mg imsidolimab, Imsidolimab 750 mg IV/200 mg SC
NCT01428661 Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder	Major Depressive Disorder	P2P3	Completed	507	RCT, Double-blind	tasimelteon, placebo
NCT04819776 Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder	Bipolar I Disorder	P3	Completed	417	RCT, Double-blind	Iloperidone, Iloperidone Placebo
NCT05361707 Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances	Autism Spectrum Disorder, Sleep Disorder	P3	Unknown	100	Open-label	Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
NCT00548340 VEC-162 Study in Adult Patients With Primary Insomnia	Primary Insomnia	P3	Completed	322	RCT, Double-blind	VEC-162 20 mg, Placebo, VEC-162 50 mg
NCT07686081 Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis	Ulcerative Colitis (UC)	P3	Not Yet Recruiting	150	RCT, Double-blind	Ponesimod, Placebo
NCT04140695 Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)	Atopic Dermatitis	P3	Terminated	87	RCT, Double-blind	Tradipitant, Placebo
NCT01218789 Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception	Non 24 Hour Sleep Wake Disorder	P3	Unknown	140	Open-label	tasimelteon
NCT00254202 Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia	Schizophrenia	P3	Completed	593	RCT, Double-blind	Iloperidone, Ziprasidone, Placebo
NCT05903924 Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness	Motion Sickness	P3	Completed	316	RCT, Double-blind	Tradipitant, Placebo
NCT04028492 Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis	Idiopathic Gastroparesis, Diabetic Gastroparesis	P3	Completed	992	RCT, Double-blind	Tradipitant, Placebo, Open Label Tradipitant
NCT01291511 Relapse Prevention Study in Patients With Schizophrenia	Schizophrenia	P3	Completed	635	RCT, Double-blind	Iloperidone, Placebo
NCT00291187 VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia	Insomnia	P3	Completed	411	RCT, Double-blind	20 mg VEC-162, 50 mg VEC-162, 100 mg VEC-162, Placebo
NCT03373201 Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia	Jet Lag Type Insomnia	P3	Completed	320	RCT, Double-blind	Tasimelteon, Placebo
NCT02231008 Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS	Smith-Magenis Syndrome, Circadian	P2P3	Completed	49	RCT, Double-blind	tasimelteon, placebo
NCT05352893 Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP	Generalized Pustular Psoriasis	P3	Completed	45	RCT, Double-blind	750 mg Imsidolimab, 300 mg Imsidolimab
NCT01163032 Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder	Non-24-Hour Sleep-Wake Disorder	P3	Completed	136	RCT, Double-blind	tasimelteon, Placebo
NCT00467441 VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness	Excessive Somnolence	P2	Completed	60	RCT, Double-blind	VSF-173
NCT04856917 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris	Acne Vulgaris	P2	Completed	123	RCT, Double-blind	Imsidolimab, Placebo
NCT04849559 Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers	Healthy Volunteer	P1P2	Completed	27	RCT, Double-blind	Tradipitant, Placebo
NCT04800237 Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety	Performance Anxiety	P2	Completed	230	RCT, Double-blind	VQW-765, Placebo
NCT04622345 Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies	Allergic Conjunctivitis	P2	Completed	47	RCT, Double-blind	VSJ-110, Placebo
NCT02970968 Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis	Gastroparesis	P2	Completed	152	RCT, Double-blind	VLY-686 (Tradipitant)
NCT04856930 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa	Hidradenitis Suppurativa	P2	Completed	149	RCT, Double-blind	Imsidolimab, Placebo
NCT04697069 A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash	Acneiform Eruptions	P2	Terminated	4	RCT, Double-blind	Imsidolimab, Placebo
NCT02004041 Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis	Treatment-resistant Pruritus Associated With Atopic Dermatitis	P2	Completed	69	RCT, Double-blind	VLY-686, Placebo
NCT03633396 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis	Palmoplantar Pustulosis	P2	Completed	59	RCT, Double-blind	Imsidolimab, Placebo
NCT02651714 Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis	Atopic Dermatitis	P2	Completed	168	RCT, Double-blind	Tradipitant, Placebo
NCT04697056 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis	Ichthyosis	P2	Terminated	5	RCT, Double-blind	Imsidolimab, placebo
NCT05344365 A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis	Parkinson Disease Psychosis	P2	Withdrawn	—	Open-label	Iloperidone
NCT03772340 Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness	Motion Sickness	P2	Completed	126	RCT, Double-blind	Tradipitant, Placebo
NCT03291041 A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder	Jet Lag Disorder	P2	Completed	25	RCT, Double-blind	Tasimelteon, Placebo
NCT03619902 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis	Generalized Pustular Psoriasis	P2	Completed	8	Open-label	Imsidolimab
NCT00490945 Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers	Circadian Rhythm Sleep Disorders	P2	Completed	45	RCT, Double-blind	VEC-162
NCT06804603 A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use	Obesity	P2	Completed	124	RCT, Double-blind	Tradipitant, Placebo
NCT06296966 A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye	Dry Eye	P2	Unknown	40	RCT, Double-blind	VSJ-110, Placebo
NCT01348100 Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients	Schizophrenia	P1P2	Completed	81	RCT, Open-label	Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone
NCT01540500 Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine	Healthy Volunteers	P1	Completed	24	Open-label	Tasimelteon, Fluvoxamine
NCT01271387 Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment	Hepatic Impairment	P1	Completed	29	Open-label	tasimelteon
NCT06323655 Evaluation of Next-Day Residual Effects of Tasimelteon Compared With Placebo and Active Control in Healthy Subjects	Healthy Volunteers	P1	Completed	48	RCT, Double-blind	Tasimelteon, Active Control Placebo, Tasimelteon Placebo, Active Control
NCT01526746 Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function	Renal Impairment	P1	Completed	32	Open-label	Tasimelteon, Tasimelteon
NCT01578057 Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol	Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol	P1	Completed	28	RCT, Double-blind	tasimelteon, Ethanol, Placebo ethanol
NCT02621385 Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects	Healthy Volunteers	P1	Completed	24	Open-label	tradipitant, Midazolam
NCT04712734 A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia	Schizophrenia	P1	Completed	42	Open-label	Iloperidone
NCT02776215 Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents	Circadian Rhythm Sleep Disorders, Non-24 Hour Sleep-Wake Disorder	P1	Completed	24	Open-label	tasimelteon
NCT01919944 Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P	Pruritus	P1	Completed	12	RCT, Double-blind	VLY-686, Placebo
NCT06494397 Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions	Schizophrenia, Bipolar I Disorder	P1	Completed	26	RCT, Open-label	VHX-896 and iloperidone, Iloperidone and VHX-896
NCT04969211 Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers	Healthy	P1	Completed	25	RCT, Open-label	VHX-896 and iloperidone, Iloperidone and VHX-896
NCT04127058 Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia	Bipolar I Disorder, Schizophrenia	P1	Completed	12	Open-label	Iloperidone
NCT01495169 Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients	Safety and Tolerability of Iloperidone	P1	Completed	33	Open-label	iloperidone (oral tablet)
NCT01402076 A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects	Healthy Volunteers	P1	Completed	24	Open-label	Tasimelteon, Rosiglitazone, Midazolam
NCT06803290 Food Effect Study of VHX-896 in Healthy Volunteers	Healthy	P1	Completed	24	RCT, Open-label	VHX-896
NCT01637636 Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.	Healthy	P1	Completed	48	Open-label	tasimelteon, tasimelteon, Rifampin, Ketoconazole
NCT01477619 Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects	Healthy Volunteers	P1	Completed	60	Open-label	Tasimelteon
NCT05572281 Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers	Healthy	P1	Completed	36	RCT, Open-label	Tasimelteon Oral Capsule, Tasimelteon Oral Suspension
NCT02560103 An Observational Study to Investigate the Effects of Rapid Transmeridian Travel	Jet Lag Disorder		Completed	119	—	—
NCT04353401 WGS Analysis of COVID-19 Positive Patients	Coronavirus Infection, COVID-19		Completed	79	—	—
NCT05922995 The Effects of Tasimelteon in Participants With REM Behavior Disorder (RBD)	REM Behavior Disorder	Early P1	Terminated	20	Open-label	Tasimelteon
NCT04474990 Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis	Gastroparesis, Diabetic Gastroparesis		AVAILABLE	—	—	Tradipitant
NCT02180451 Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)	Smith Magenis Syndrome		Unknown	8	—	—